{
    "clinical_study": {
        "@rank": "164843", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "URC102", 
                "arm_group_type": "Active Comparator", 
                "description": "URC102"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the safety, tolerability, PK and PD of URC102 in healthy subjects. To evaluate the\n      food effect on PK."
        }, 
        "brief_title": "Phase 1 Study of URC102 in Healthy Subjects", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers\n\n        Exclusion Criteria:\n\n          -  Received other investigational drug within 12 weeks prior to the first dose of study\n             drug"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01953497", 
            "org_study_id": "URC001KR"
        }, 
        "intervention": [
            {
                "arm_group_label": "URC102", 
                "intervention_name": "URC102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Placebo-controlled, Randomized, Double Blind, Single or Multiple Dose Study of URC102 in Healthy Male Volunteers of Korean and Caucasian to Assess Safety, Pharmacokinetics and Pharmacodynamics", 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Kyung-Sang Yu, MD, PhD, MBA", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety(MFDS)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with AE", 
            "safety_issue": "No", 
            "time_frame": "1 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01953497"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma URC102 concentration", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Blood uric acid", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }
        ], 
        "source": "JW Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "JW Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}